life scienc tool diagnost
price month
 close
refin model adjust model reflect increment
disclosur wba earn call make chang
ep decreas ep
lower profit oper growth like obscur
increment expens expect reimburs pressur continu
weigh profit particularli us retail pharmaci segment
among factor also incorpor higher tax rate vs
previou estim higher share base
commit repurchas billion share vs prior estim
billion note also adjust outer-year estim incorpor
increas tax rate non-recurring discret item
subsid progress restructur plan partial off-set
lower share base billion share repurchas annual vs prior
billion annual risk competit
valuat metric
number share
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
walgreen co togeth subsidiari oper drugstor
chain unit state compani provid custom
multichannel access consum good servic
pharmaci health well servic commun across
better fundament perform sentiment could drive upsid
target price blue sky scenario
weaker fundament perform sentiment could drive
downsid target price grey sky scenario
 close
compani mention price
erin wilson wright certifi view express report accur reflect person view subject compani
secur part compens directli indirectli relat specif recommend view express
report
